entertainment -WSS

entertainment

author：comprehensive 2025-09-27 06:03:12 - browse：8233

Three boxes of Breyanzi on a dark blue background — biotech coverage from STAT — The FDA is looking into adverse events involving a number of CAR-T therapies, including Breyanzi. Illustration: STAT; Source: Business Wire

The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma, a blood cancer.

“Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action,” the agency said in a statement.

The agency noted that it is investigating reports of T cell lymphoma, including cancer cells carrying the engineered T cells, in patients who received CAR-T therapy. Experts in the field, which has produced multiple approved products to treat blood cancer, expressed surprise and puzzlement at the announcement, saying that they had not previously seen data about the risk.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： CMS should re

WSS

Why Novartis is changing the name of its research labs

Weighted lottery helped low

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

The woman behind the Dana Farber

Ethical issues complicate the benefits of medical crowdfunding

hotspot

entertainment

hotspot

Alkermes shareholders re

What American doctors can learn from their Israeli counterparts

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Advances in CAR

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Wildfire smoke exposes gaps in outdoor worker protections

What drug price negotiations mean for Medicare Part D

Duchenne breakthrough therapy leaves behind pioneering families

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

leisure time

Amazon on where the company's health care bets are headed next

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

In diabetes hearing, Sanders takes on a new foe: food makers

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

NIH nominee Bertagnolli will get October confirmation hearing

Radiology is caught between AI's potential and concern for patients

explore

knowledge

Wikipedia

Wikipedia